Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07083427

CAPA In-vitro Oocyte Maturation (CUHK Medical Centre Limited)

In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Infertility, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Infertility Urogenital Diseases

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Prince of Wales Hospital

Hong Kong

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged from 18-50 years old
  • Patients seek fertility preservation services
  • Patients seek oocyte retrieval services

Exclusion criteria

  • Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Treatment and study plan

CAPA-IVM

Other

In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

Primary outcomes

  1. Number of mature oocytes

    Time frame: 1 week

    Number of mature oocytes after IVM

Study contacts

Contact information is provided by the study sponsor or research team.

Pui Wah Jacqueline Chung, MBBS

CONTACT

[email protected]

3505 2745

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Official study title

CAPA In-vitro Oocyte Maturation

Important dates

Study start
2025
Primary completion
2035
Study completion
2036
First posted
Jul 24, 2025
Registry last updated
Jul 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.